Q4 and Full Year 2025 Financial Results Align Technology, Inc. February 4, 2026 ©2026, Align Technology Inc. All rights reserved. ©2026 Align Technology Inc. All rights reserved. 1 Q4 2025 Conference Call Details Conference Call Speakers: Webcast Archive: • Audio webcast archive will be available at http://investor.aligntech.com for one month Contacts Website: http://investor.aligntech.com Email: investorinfo@aligntech.com Tel: (602) 742-2000 Corporate and Investor Communications: ©2026 Align Technology Inc ...

Core Viewpoint - Iradimed Corporation will release its 2025 fourth quarter and full year financial results on February 10, 2026, followed by a conference call to discuss the results and answer questions [1]. Company Overview - Iradimed Corporation is a leader in developing MRI-compatible medical devices, specifically known for its non-magnetic intravenous infusion pump system designed for safe use during MRI procedures [3]. - The company was the first to create an infusion delivery system that mitigates dangers associated with standard infusion pumps during MRI, which can cause radio frequency interference [3]. - The patented MRidium® MRI-compatible IV infusion pump system features a non-magnetic ultrasonic motor and non-ferrous parts, ensuring safe and reliable delivery of anesthesia and IV fluids during MRI scans [3]. Product Details - The 3880 MRI-compatible patient vital signs monitoring system is designed with non-magnetic components, allowing it to operate in magnetic fields up to 30,000 gauss, ensuring patient safety during MRI procedures [4]. - The Iradimed 3880 system features wireless ECG, SpO2 monitoring, non-magnetic respiratory CO2 measurement, and blood pressure monitoring, facilitating uninterrupted vital signs monitoring for critically ill patients [4]. - The compact design of the Iradimed 3880 allows for easy transport with patients, enhancing safety and reducing time away from critical care units [4].

MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025. Key Highlights "Over the past 90 days, I've met extensively with Accuray teams and customers across all major regions. Their insights have directly informed the decisive actions we've already taken — from reorganizing our commercial structure to refining our nearterm product and service investment priorities. We moved quickly and with discipline acr ...

Core Insights - Boston Scientific Corporation reported fourth-quarter results that surpassed revenue and earnings expectations, but weakness in its electrophysiology business negatively impacted investor sentiment, leading to a more than 9% decline in shares during premarket trading [1] Financial Performance - The company reported fourth-quarter revenue of $5.29 billion, slightly above Stifel's estimate of $5.25 billion and the consensus forecast of $5.28 billion, with organic revenue growth for the quarter reaching 15.9% [1] - Earnings per share were reported at $0.80, exceeding Stifel's estimate of $0.77 and the consensus forecast of $0.78, attributed to a lower-than-expected effective tax rate of approximately 9.3% [3] Segment Performance - The electrophysiology segment, which represented roughly 17% of total quarterly revenue, underperformed expectations with segment revenue totaling $890 million, significantly below the consensus estimate of $933 million, primarily due to softer demand in the U.S. market [2] Future Guidance - For 2026, the company guided for organic revenue growth of 10% to 11% and earnings per share in the range of $3.43 to $3.49, with first-quarter organic revenue growth expected to range from 8.5% to 10%, indicating stronger growth anticipated in the latter half of the year [3]

Core Insights - Utah Medical Products, Inc. (UTMD) shares increased by 2% following the release of its fourth-quarter and full-year 2025 earnings, outperforming the S&P 500 index's 0.2% growth during the same period [1] - Over the past month, UTMD shares rose by 7.6%, significantly exceeding the S&P 500's 1.5% increase [1] Financial Performance - For Q4 2025, UTMD reported earnings per share (EPS) of 80.2 cents, a decrease of 6.3% from 85.7 cents in Q4 2024 [2] - Revenues for the quarter were $9 million, reflecting a 1.2% decline from $9.2 million in the same period a year ago [2] - Gross profit decreased by 1.1% to $5.26 million, down from $5.32 million in Q4 2024 [3] - Operating income fell 16.7% year over year to $2.4 million from $2.9 million, primarily due to increased operating expenses [3] - Net income was $2.6 million, an 11.6% decline from $2.9 million in the prior-year quarter [3] Key Business Metrics - Gross profit margin remained strong at 58.2%, nearly unchanged from 58.1% in the prior-year quarter [4] - Operating income margin declined to 27% from 32%, and net income margin fell to 28.4% from 31.7% [4] - Adjusted consolidated EBITDA for the quarter was $4 million, down 10% from $4.4 million a year ago, with EBITDA as a percentage of sales declining to 43.8% from 48.1% [4] Sales Performance - Domestic U.S. sales in Q4 declined 4.9% to $5.5 million from $5.7 million, with non-Filshie device sales accounting for most of the drop [5] - OEM sales decreased by 31.5% year over year, while Filshie device sales in the U.S. increased by 21.6% [5] - Outside the U.S. sales rose 4.9% to $3.6 million, largely due to favorable foreign exchange rates, but on a constant currency basis, OUS sales were up only 0.5% [5] Management Commentary - Management indicated that the fourth quarter provided a normalized comparison, with no sales to UTMD's China distributor in either Q4 2025 or Q4 2024, allowing margins to stabilize despite cost pressures [6] - Cost-of-living salary increases and raw material inflation continued to impact results, but effective cost containment helped prevent further deterioration [6] Operating Expenses - Operating expenses increased due to higher general and administrative (G&A) costs, including a $0.2 million charge related to an embezzlement case and a $0.4 million write-off tied to cancellation fees [7] - G&A expenses represented 23.2% of sales in Q4, up from 19.3% in the prior-year quarter [7] Factors Influencing Results - Revenue decline was primarily driven by softness in U.S. sales of non-Filshie medical devices and OEM components, with U.S. Filshie sales growth not sufficient to offset declines in other areas [8] - Favorable foreign exchange rates provided a modest benefit to reported international sales, particularly in Europe [8] Legal and Litigation Costs - Legal costs related to product liability litigation increased slightly to $0.4 million from $0.3 million the previous year, with 14 of 19 pending court cases dismissed by the end of January 2026 [9][10] Full-Year Performance - Full-year sales totaled $38.5 million, a 5.8% year-over-year decline from $40.9 million in 2024, with net income falling 18.7% to $11.3 million [11] - EPS dropped 12.1% year over year to $3.48, and gross margin declined to 57.1% from 59% in 2024 [11] Guidance and Future Outlook - Management expects sales to PendoTECH and the China distributor to remain at zero in 2026, aiming to offset losses with new product introductions and organic growth in Filshie sales [12] - There is substantial uncertainty regarding the recovery [12] Share Repurchase and Financial Position - During Q4 2025, UTMD repurchased 17,951 shares at an average cost of $55.35 per share, totaling $1 million [13] - The company ended the year with $85.8 million in cash and investments, up $2.8 million from the end of 2024, and no debt [14]

Core Insights - Boston Scientific achieved over $20 billion in sales for 2025, marking a mid-teens growth for the second consecutive year, driven by innovation and execution across business units [6][30] - The company reported a Q4 operational sales growth of 14% and organic sales growth of 13%, exceeding guidance [6][29] - Full year 2025 adjusted EPS grew 22% to $3.06, surpassing guidance, with operational sales growth of 19% and organic sales growth of 16% [7][30] Financial Performance - Q4 consolidated revenue reached $5.286 billion, representing a 15.9% reported growth, with operational revenue growth of 14.3% [29] - Full year 2025 consolidated revenue was $20.74 billion, a 19.9% increase, with operational revenue growth of 19.2% [30] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [31] Business Unit Highlights - The U.S. market saw a 17% growth in Q4 and 26% for the full year, particularly strong in EP, WATCHMAN, and ICTx [8] - The Cardiovascular segment delivered 16% operational growth in Q4 and 22% operational growth for the full year [14] - WATCHMAN business grew 29% in Q4, with strong adoption of concomitant procedures [22] Regional Performance - Europe, Middle East, and Africa (EMEA) grew 5% in Q4 and 3% for the full year, with high single-digit growth expected excluding the impact of product discontinuation [9] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, driven by strong performance in Japan and China [10][11] Future Outlook - For Q1 2026, the company expects organic growth of 8.5% to 10% and for the full year, guidance is set at 10% to 11% [8][36] - Adjusted EPS for 2026 is projected to be between $3.43 and $3.49, indicating a growth of 12% to 14% [38] - The company anticipates continued momentum in EP and WATCHMAN, with expectations for the market to grow approximately 15% in 2026 [26][72] Strategic Acquisitions - Boston Scientific announced agreements to acquire Penumbra and Valencia Technologies, expected to close in 2026, enhancing its portfolio in high-growth segments [15][35] - The acquisition of Nalu Medical has been completed, complementing the neuromodulation pain franchise [35]

Core Insights - GE HealthCare (GEHC) reported Q4 2025 adjusted EPS of $1.44, exceeding the Zacks Consensus Estimate of $1.43 by 0.7%, but down 0.7% year over year. GAAP EPS was $1.29, a decline of 17.8% from the previous year [1] - For the full year, adjusted EPS increased by 2.2% to $4.59, while GAAP EPS rose 4.8% to $4.55 [1] Revenue Details - Revenues reached $5.7 billion, reflecting a 7.1% year-over-year increase on a reported basis and 4.8% organically, surpassing the Zacks Consensus Estimate by 1.9%. Total company orders grew 2% year over year organically, with a book-to-bill ratio of 1.06X [2][7] - Full-year revenues increased by 4.8% to $20.6 billion, with organic sales growth of 3.5% [3] Segmental Performance - Imaging segment revenues were $2.55 billion, up 6.6% year over year, while segment EBIT decreased by 12.5% to $264 million [4] - Advanced Visualization Solutions generated $1.53 billion in revenues, a 5.9% increase year over year, with EBIT rising 0.7% to $376 million [4] - Patient Care Solutions revenues fell to $825 million, down 0.3% year over year, with EBIT declining 29.6% to $74 million [5] - Pharmaceutical Diagnostics saw revenues of $790 million, up 22.3% year over year, with EBIT increasing by 10% to $234 million [5] Margins and Financial Position - The net income margin was 10.3%, down 320 basis points from the prior year due to tariffs and product mix, although volume and pricing benefits partially offset this decline [6][7] - At the end of Q4, GEHC had cash, cash equivalents, and investments totaling $4.51 billion, an increase from $4.03 billion in the previous quarter. Total assets rose to $36.91 billion from $36.13 billion sequentially [9] 2026 Guidance - GE HealthCare anticipates organic revenue growth of 3-4% for 2026 and adjusted EPS in the range of $4.95-$5.15, indicating a year-over-year growth of 7.9-12.3%. The Zacks Consensus Estimate for 2026 revenues and EPS is $21.38 billion and $4.94, respectively [10] Strategic Initiatives - The company is focused on inorganic growth through acquisitions, having acquired Nihon Medi-Physics and icometrix in 2025, and is set to acquire Intelerad in the first half of 2026 to enhance its cloud-enabled enterprise imaging capabilities [14] - Continued investment in R&D and new product introductions, including advanced imaging systems and AI-enabled diagnostics, underscores GE HealthCare's commitment to precision care and digital transformation [15]

Economic Indicators - Initial weekly unemployment claims are expected to increase by 3,000 to 212,000 [1] - The University of Michigan Jan consumer sentiment index is expected to fall by 1.4 to 55.0 [1] - US MBA mortgage applications fell by 8.9% in the week ended January 30, with the purchase mortgage sub-index down by 14.4% and the refinancing sub-index down by 4.7% [1] Treasury and Government Funding - Next week's quarterly refunding will total $125 billion in sales of T-notes and T-bonds, with auction sizes expected to remain unchanged for the next several quarters [2] - Market sentiment improved following the end of the partial US government shutdown, with funding for the Department of Homeland Security through February 13 and the rest of the government funded through September 30 [2] Stock Market Performance - Stock indexes are mixed, with the Nasdaq 100 falling to a 2-week low due to investor rotation out of high-flying chipmakers and AI-infrastructure stocks [4] - The S&P 500 Index is down by 0.11%, while the Dow Jones Industrials Index is up by 0.69% and the Nasdaq 100 Index is down by 1.05% [5] Earnings Reports - Q4 earnings season is in full swing, with 80% of the 195 S&P 500 companies that have reported beating expectations [6] - S&P earnings growth is expected to climb by 8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth [6] - Super Micro Computer is up more than 13% after forecasting Q3 net sales well above expectations, while Advanced Micro Devices is down more than 15% after a weak Q1 sales forecast [4][15] Company-Specific Movements - Eli Lilly is up more than 10% after reporting Q4 revenue of $19.29 billion, stronger than the consensus of $18.01 billion [16] - Boston Scientific is down more than 15% after forecasting full-year adjusted EPS below consensus [13][14] - Silicon Laboratories is up more than 49% after agreeing to be acquired by Texas Instruments for $7.5 billion [15]

Core Insights - Abbott has initiated a recall of specific glucose monitoring sensors due to their association with seven reported deaths and 860 serious injuries, as stated by the U.S. health regulator [1] Company Summary - The recall involves glucose monitoring sensors produced by Abbott, highlighting significant safety concerns linked to the devices [1] - The U.S. health regulator's announcement indicates a serious regulatory response to the incidents associated with Abbott's products [1] Industry Summary - The incident raises broader implications for the medical device industry, particularly in the area of glucose monitoring technology, emphasizing the need for stringent safety measures [1] - The reported deaths and injuries could lead to increased scrutiny and regulatory oversight across similar medical devices in the market [1]

Core Viewpoint - The medical-device maker reported a 16% increase in sales but provided a weak forecast for the year, leading to a decline in shares during premarket trading [1] Group 1 - Sales increased by 16% year-over-year, indicating strong demand for the company's products [1] - The company issued a soft forecast for the upcoming year, which has raised concerns among investors [1] - Following the forecast announcement, shares of the company experienced a drop in premarket trading [1]